Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd, an innovator in LAG-3 immunotherapies, has announced the forthcoming initiation of a groundbreaking Phase I clinical trial in the Netherlands for its novel autoimmune treatment, IMP761. Gearing up to commence patient enrollment in Q3 2024, this first-in-human study targets the underlying cause of autoimmune diseases by silencing disease-causing T cells. The anticipation is high as this development could herald a new era in the treatment of conditions such as rheumatoid arthritis and Type 1 diabetes.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
